Cocrystal Pharma, Inc. (COCP) News
Filter COCP News Items
COCP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COCP News Highlights
- COCP's 30 day story count now stands at 4.
- Over the past 28 days, the trend for COCP's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about COCP are DRUG, LTRN and RNA.
Latest COCP News From Around the Web
Below are the latest news stories about Cocrystal Pharma Inc that investors may wish to consider to help them evaluate COCP as an investment opportunity.
COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Founded in 2006, Cocrystal Pharma (NASDAQ:COCP) is a clinical stage biotechnology company focused on novel antiviral treatments in the areas of coronavirus, influenza, hepatitis, and norovirus. The company has a proprietary drug discovery platform technology that provides more rapid and efficient drug discoveries. The company has |
Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Lantern Pharma (LTRN)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and Lantern Pharma (LTRN – Research Report) with bullish sentiments. Cocrystal Pharma (COCP) In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma, with a price target of $5.00. The company's shares closed last Monday at $0.55, close to its 52-week low of $0.47. According to TipRanks. |
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19Cocrystal Pharma Inc (NASDAQ: COCP) has selected two investigational novel antiviral drug candidates for further development as oral treatments for COVID-19. CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. Cocrystal plans to initiate a first-in-human trial with one selected candidate as soon as possible this year. Although CDI-988 and CDI-873 are chemically differentiated, both exhibited superior in vit |
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug ProgramNovel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity against all variants of concern including Omicron Clinical trials with oral program and CDI-45204 inhalation/pulmonary-delivered COVID-19 antiviral candidates expected to begin in 2022 BOTHELL, Wash., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) |
SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance RangePresenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern TimeBOULDER, Colo., Jan. 11, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the year ending December 31st, 2021. Preliminary, unaudited revenue for the full year 2021 is expected to exceed $79 million, the upper end of SomaLogic’s previously raised 2021 revenue guidance range |
SomaLogic Announces Appointment of Adam Taich as Chief Business OfficerBOULDER, Colo., Jan. 10, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has joined the company as the Chief Business Officer. In this newly created role, Adam will have broad responsibility across SomaLogic’s rapidly growing business to drive the company’s strategic and business development goals. He will also serve as a member of SomaLogic’s Executive Committee. Adam will report to SomaLogic Chief Executive Offic |
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces receipt of guidance from the U.S. Food and Drug Administration (FDA) for the further development of CDI-45205, Cocrystal’s novel SARS-CoV-2 main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal/pulmonary delivery. The FDA’s guidan |
Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual ConferenceBOTHELL, Wash., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the Company’s presentation will be available on the IR Calendar section of the Cocrystal Pharma website beginning Monday, January 10, 2022 at 7:00 a.m. Eastern time. “This year promises to be highly eventful as we plan to ini |
Cocrystal''s COVID-19 Antiviral Candidate Shows Potency Against Omicron VariantCocrystal Pharma Inc''s (NASDAQ: COCP ) COVID-19 antiviral candidate has shown antiviral potency against the omicron variant in vitro studies. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants, including Delta, Alpha, Beta, and Gamma . Cocrystal expects to initiate Phase 1 clinical studies with Full story available on Benzinga.com |
Cocrystal Pharmas COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron VariantAntiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma |